TScan Therapeutics, Inc. (TCRX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TScan Therapeutics, Inc., a Delaware corporation, on August 14, 2025. The report discloses a corporate governance event regarding the appointment of a new Principal Accounting Officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
On August 14, 2025, the Board of Directors appointed Leiden Dworak as the Company's Principal Accounting Officer, effective immediately. Consequently, Jason A. Amello ceased to serve as Principal Accounting Officer but continues in his roles as Chief Financial Officer and Principal Financial Officer.
Management Commentary and Risks
Mr. Dworak brings 17 years of experience in financial infrastructure for biotechnology and life sciences. His background includes roles at AVROBIO, Inc., Moderna, Inc., Merrimack Pharmaceuticals, SeraCare Life Sciences, and Boston Scientific Corporation. The filing states there are no family relationships between Mr. Dworak and other directors or officers, and no related party transactions requiring disclosure.
Investor Verification Checklist
- Confirm the effective date of Leiden Dworak's appointment as Principal Accounting Officer (August 14, 2025).
- Verify that Jason A. Amello retains his position as Chief Financial Officer.
- Review Mr. Dworak's prior experience at AVROBIO and Moderna for relevant industry expertise.
- Note the absence of financial data in this specific filing; refer to recent 10-Q or 10-K filings for financial metrics.